Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-748-5975
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees33
OptionableOptionable
Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions
What is Dova Pharmaceuticals' stock symbol?
Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."
How were Dova Pharmaceuticals' earnings last quarter?
Dova Pharmaceuticals Inc (NASDAQ:DOVA) posted its earnings results on Thursday, November, 8th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.81) by $0.12. The business earned $2.93 million during the quarter, compared to analyst estimates of $2.66 million. View Dova Pharmaceuticals' Earnings History.
When is Dova Pharmaceuticals' next earnings date?
What price target have analysts set for DOVA?
6 Wall Street analysts have issued twelve-month price targets for Dova Pharmaceuticals' shares. Their predictions range from $18.00 to $44.00. On average, they expect Dova Pharmaceuticals' share price to reach $30.5714 in the next twelve months. This suggests a possible upside of 306.5% from the stock's current price. View Analyst Price Targets for Dova Pharmaceuticals.
What is the consensus analysts' recommendation for Dova Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dova Pharmaceuticals.
What are Wall Street analysts saying about Dova Pharmaceuticals stock?
Here are some recent quotes from research analysts about Dova Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. " (10/30/2018)
- 2. Jefferies Financial Group Inc analysts commented, "About 6 weeks into Doptelet launch, DOVA has been pleased with reimbursement levels (not seeing pushback from payers); plans to provide some key metrics, including % Rx getting reimbursed by payers on 2Q18 call." (7/15/2018)
Has Dova Pharmaceuticals been receiving favorable news coverage?
News headlines about DOVA stock have trended very positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a media sentiment score of 3.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Dova Pharmaceuticals' key competitors?
Some companies that are related to Dova Pharmaceuticals include Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Athenex (ATNX), Radius Health (RDUS), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), ImmunoGen (IMGN), Epizyme (EPZM), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX) and G1 Therapeutics (GTHX).
Who are Dova Pharmaceuticals' key executives?
Dova Pharmaceuticals' management team includes the folowing people:
- Dr. Lee F. Allen, Chief Medical Officer (Age 67)
- Dr. David S. Zaccardelli, Pres & CEO (Age 54)
- Mr. Mark W. Hahn, CFO & Sec. (Age 56)
- Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)
- Mr. Jason Hoitt, Chief Commercial Officer
When did Dova Pharmaceuticals IPO?
(DOVA) raised $66 million in an initial public offering on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.
How do I buy shares of Dova Pharmaceuticals?
Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dova Pharmaceuticals' stock price today?
One share of DOVA stock can currently be purchased for approximately $7.52.
How big of a company is Dova Pharmaceuticals?
Dova Pharmaceuticals has a market capitalization of $212.09 million. The company earns $-29,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Dova Pharmaceuticals employs 33 workers across the globe.
What is Dova Pharmaceuticals' official website?
How can I contact Dova Pharmaceuticals?
Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]
MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
